EA201892212A1 - Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b - Google Patents

Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b

Info

Publication number
EA201892212A1
EA201892212A1 EA201892212A EA201892212A EA201892212A1 EA 201892212 A1 EA201892212 A1 EA 201892212A1 EA 201892212 A EA201892212 A EA 201892212A EA 201892212 A EA201892212 A EA 201892212A EA 201892212 A1 EA201892212 A1 EA 201892212A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
composition
pharmaceutical composition
hepatitis
antigen
Prior art date
Application number
EA201892212A
Other languages
English (en)
Russian (ru)
Inventor
Хулио Сесар Агилар Рубидо
Ядира Лобайна Мато
Энрике Иглесиас Перес
Эдуардо Пентон Ариас
Херардо Энрике Гильен Ньето
Хорхе Агустин Агиар Сантиаго
Сонья Гонсалес Бланко
Хорхе Вальдес Эрнандес
Мариэла Васкес Кастильо
Original Assignee
Сентро Де Инхеньерия Хенетика И Биотекнолохия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентро Де Инхеньерия Хенетика И Биотекнолохия filed Critical Сентро Де Инхеньерия Хенетика И Биотекнолохия
Publication of EA201892212A1 publication Critical patent/EA201892212A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201892212A 2016-03-31 2017-03-14 Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b EA201892212A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
EA201892212A1 true EA201892212A1 (ru) 2019-03-29

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892212A EA201892212A1 (ru) 2016-03-31 2017-03-14 Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b

Country Status (16)

Country Link
US (2) US11491218B2 (enExample)
EP (1) EP3437654B1 (enExample)
JP (1) JP6981992B2 (enExample)
KR (1) KR20180125985A (enExample)
CN (1) CN109219449B (enExample)
AR (1) AR108009A1 (enExample)
AU (1) AU2017243136B2 (enExample)
CU (1) CU24454B1 (enExample)
EA (1) EA201892212A1 (enExample)
ES (1) ES2965709T3 (enExample)
MX (1) MX2018011793A (enExample)
MY (1) MY202118A (enExample)
TW (1) TWI755383B (enExample)
UA (1) UA128952C2 (enExample)
WO (1) WO2017167317A1 (enExample)
ZA (1) ZA201806325B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548328A (ja) * 2019-09-23 2022-11-17 アセンド バイオテクノロジー インク 生分解性ナノ複合体ワクチン、ｂ型肝炎ウイルス複製およびｂ型肝炎ウイルス表面抗原分泌の抑制方法
JP2023509966A (ja) 2020-01-10 2023-03-10 カロジェン コーポレイション 腫瘍溶解性ウイルス様小胞の組成物および使用方法
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
EP4465999A4 (en) * 2022-02-22 2025-12-24 Carogen Corp Polyvalent Virus Vesicle (VLV) Platform for Infectious Diseases and Cancer Immunotherapy Applications
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN104338132A (zh) * 2013-07-26 2015-02-11 复旦大学 一种病毒免疫治疗药物复合物及其用途

Also Published As

Publication number Publication date
CU24454B1 (es) 2019-11-04
US11759517B2 (en) 2023-09-19
US20200297840A1 (en) 2020-09-24
BR112018069738A2 (pt) 2019-02-05
CU20160038A7 (es) 2017-11-07
CN109219449A (zh) 2019-01-15
EP3437654B1 (en) 2023-09-20
JP6981992B2 (ja) 2021-12-17
JP2019510064A (ja) 2019-04-11
KR20180125985A (ko) 2018-11-26
AR108009A1 (es) 2018-07-04
WO2017167317A1 (es) 2017-10-05
AU2017243136B2 (en) 2022-02-17
CN109219449B (zh) 2022-08-30
US20220193228A1 (en) 2022-06-23
TWI755383B (zh) 2022-02-21
EP3437654A1 (en) 2019-02-06
ES2965709T3 (es) 2024-04-16
MY202118A (en) 2024-04-04
MX2018011793A (es) 2018-12-17
HK1259329A1 (zh) 2019-11-29
ZA201806325B (en) 2020-08-26
AU2017243136A1 (en) 2018-10-11
US11491218B2 (en) 2022-11-08
TW201735945A (zh) 2017-10-16
CA3017778A1 (en) 2017-10-05
UA128952C2 (uk) 2024-12-11

Similar Documents

Publication Publication Date Title
EA201892212A1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
Kim et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection
JP2016128513A5 (enExample)
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2017019891A3 (en) Compositions and methods for silencing hepatitis b virus gene expression
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA202192512A1 (ru) Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
EA201500114A1 (ru) Композиция антитела для предупреждения или лечения инфекции мутантным вирусом гепатита b
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
EA201290556A1 (ru) Оральная лекарственная форма, включающая энтекавир
JP2019510064A5 (enExample)
JP2023012539A (ja) 経鼻ｂ型肝炎ワクチン組成物およびその製造方法
MX2021005588A (es) Composiciones inmunogenicas para el tratamiento de la hepatitis b.
WO2018066891A3 (ko) 인터페론 베타 변이체의 안정화 제제
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
PH12020500194A1 (en) Malaria vaccine
UY31574A1 (es) Vacunas contra la malaria
CN104056266A (zh) 新喋呤佐剂及含新喋呤佐剂的疫苗
Lee et al. Effect of apoptosis‐associated speck‐like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant
WO2018056528A3 (ko) 인플루엔자 b 백신
RU2015115520A (ru) Рекомбинантная вакцина для профилактики вирусного гепатита В (Варианты)
CN103751777B (zh) 甘草酸二铵佐剂及含甘草酸二铵佐剂的疫苗
Bijani et al. Comparison of the efficacy of hepatitis B vaccination by different routes of immunization
Sbidian Influenza A virus vaccine H1N1